Zanubrutinib and venetoclax as initial therapy for CLL/SLL with obinutuzumab triplet consolidation in patients with detectable minimal residual disease (BruVenG).
Observational analysis found high rates of uMRD in patients with CLL/SLL treated with combined venetoclax and obinutuzumab, suggesting effective response adaptation.
Key Points
Efficacy data indicate 97% overall response rate for CLL/SLL treatment using venetoclax and obinutuzumab.
Among 20 evaluable patients, 35% achieved complete response and 30% reached minimal residual disease by bone marrow assessment.
Analysis included 45 untreated patients, with median follow-up of 13.1 months to assess safety and effectiveness of the triplet regimen.
Findings highlight the potential for optimizing CLL/SLL treatment with response-adapted therapy to minimize residual disease and toxicity.